2017年晚期胸部恶性肿瘤管理进展
本文综述2017年晚期胸部恶性肿瘤治疗进展。免疫检查点抑制剂在NSCLC中显著改善缓解率和总生存,尤其在PD-L1表达≥50%的一线患者及经治患者中。新一代TKI对EGFR突变和ALK重排NSCLC显示优于一代TKI的缓解率和无进展生存,但最佳治疗顺序尚无定论。
要点
- 免疫检查点抑制剂在NSCLC中显著改善缓解和总生存
- 新一代TKI对EGFR突变和ALK重排NSCLC优于一代TKI
- 免疫治疗和靶向治疗的最佳组合与顺序是未来挑战
核心结论
- 胸部肿瘤领域即将迎来突破,为医生和患者提供许多有希望的新治疗选择。
- 免疫治疗敏感或耐药的预测生物标志物表征,以及免疫检查点抑制剂最佳组合和癌基因 addicted NSCLC 最佳治疗顺序的确定,是胸部肿瘤领域最艰巨的 upcoming 挑战。
研究设计与样本
- 本文为综述,总结2017年晚期胸部恶性肿瘤管理进展。
主要发现
- 免疫检查点抑制剂在未经选择的经治NSCLC患者和PD-L1表达≥50%的未经治疗NSCLC患者中均带来缓解和总生存的显著改善。
- 抗PD-1/PD-L1药物与化疗或抗CTLA-4抑制剂的新组合报告了令人信服的初步结果。
- 免疫检查点抑制剂的成功似乎扩展至SCLC、间皮瘤或胸腺肿瘤患者。
- 在SCLC中,实验性靶向治疗rovalpituzumab teserine和新型化疗药lurbinectedin报告了令人鼓舞的活性。
- 对于癌基因 addicted NSCLC,新一代TKI(如osimertinib或alectinib)在EGFR突变和ALK重排NSCLC患者中较一代TKI显示更高的缓解率和无进展生存。
关键数值与推荐
- NSCLC中免疫检查点抑制剂在PD-L1表达≥50%的未经治疗患者中改善缓解和总生存。
- 新一代TKI(osimertinib或alectinib)在EGFR突变和ALK重排NSCLC中较一代TKI提高缓解率和无进展生存。
- 由于缺乏成熟的总生存数据,且这些药物在既往暴露于一代或二代TKI的NSCLC患者中高效,尚不能就最佳治疗顺序得出明确结论。
- 新癌基因如突变BRAF、MET、HER2和RET重排已加入潜在可靶向驱动基因列表。
临床怎么用
- 对PD-L1表达≥50%的未经治疗NSCLC患者可考虑免疫检查点抑制剂治疗。
- 对EGFR突变和ALK重排NSCLC,新一代TKI较一代TKI显示更优缓解率和无进展生存。
- 免疫检查点抑制剂联合化疗或抗CTLA-4抑制剂的新组合显示初步有希望结果。
- SCLC、间皮瘤和胸腺肿瘤患者可能从免疫检查点抑制剂中获益。
- 癌基因 addicted NSCLC的最佳治疗顺序尚待确定,需综合考虑既往TKI暴露和高疗效药物。
局限性
- 缺乏成熟的总生存数据,尚不能就癌基因 addicted NSCLC的最佳治疗顺序得出明确结论。
- 免疫治疗敏感或耐药的预测生物标志物表征尚未完成。
- 免疫检查点抑制剂的最佳治疗组合尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment paradigm of NSCLC underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival both in unselected pretreated patients and in untreated patients with programmed death ligand 1 expression of 50% or more. Furthermore, compelling preliminary results were reported for new combinations of anti-programmed cell death 1/programmed death ligand 1 agents with chemotherapy or anti-cytotoxic T-lymphocyte associated protein 4 inhibitors. The success of the ICIs appeared to extend to patients with SCLC, mesothelioma, or thymic tumors. Furthermore, in SCLC, encouraging activity was reported for an experimental target therapy (rovalpituzumab teserine) and a new chemotherapeutic agent (lurbinectedin). For oncogene-addicted NSCLC, next-generation tyrosine kinase inhibitors (TKIs) (such as osimertinib or alectinib) have demonstrated increased response rates and progression-free survival compared with first-generation TKIs in patients with both EGFR-mutated and ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC. However, because of the lack of mature overall survival data and considering the high efficacy of these drugs in patients with NSCLC previously exposed to first- or second-generation TKIs, definitive conclusions concerning the best treatment sequence cannot yet be drawn. In addition, new oncogenes such as mutant BRAF, tyrosine-protein kinase met gene (MET) and erb-b2 receptor tyrosine kinase 2 gene (HER2), and ret proto-oncogene (RET) rearrangements have joined the list of potential targetable drivers. In conclusion, the field of thoracic oncology is on the verge of a breakthrough that will open up many promising new therapeutic options for physicians and patients. The characterization of biomarkers predictive of sensitivity or resistance to immunotherapy and the identification of the optimal therapeutic combinations (for ICIs) and treatment sequence (for oncogene-addicted NSCLC) represent the toughest upcoming challenges in the domain of thoracic oncology.
引用
- Ferrara R, Mezquita L, Besse B, et al. Progress in the Management of Advanced Thoracic Malignancies in 2017. J Thorac Oncol. 2018. PMID: 29331646. doi:10.1016/j.jtho.2018.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。